NCT03497442View on ClinicalTrials.gov

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 12, 2018

Primary Completion Date

March 25, 2019

Study Completion Date

March 25, 2019

Conditions
FlushingAlcohol-Related DisordersAldehyde Dehydrogenase Deficiency
Interventions
DRUG

Brimonidine Tartrate

Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.

DRUG

Placebo Vehicle Gel

Vehicle Gel

Trial Locations (1)

94115

UC, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT03497442 - Treatment of Asian Flushing Syndrome With Topical Alpha Agonists | Biotech Hunter | Biotech Hunter